Quasar is the firm created by Banco Santander in association with Blackstone, who holds 51%, to deal with Banco Popular's toxic assets. In 2019, Quasar suffered losses of €1229 million and covid19 may increase them a lot. If Blackstone decides to bring the Spanish bank to court, SAN could face subpoenas and legal amendments that could bring down SAN's shareprice...
FUNDAMENTAL ANALYSIS Palantir's 2021 outlook disappoints investors: Year-over-year revenue growth of greater than 30% (instead of greater than 47% as it's been in 2020) And for Q1 2021, they expect: Year-over-year revenue growth of 45%. Adjusted operating margin of 23%. For the fourth quarter, Palantir reported an adjusted profit of 6 cents per share,...
Today, the company has passed 0.236 Fib retracement level and now is touching the upper boundary of the bearish channel it's been immersed since Nov 23, 2020. RSI 14 is about to surpass 70 level, which usually means a change of trend and that would be bad news for IAG's investors. Either technical and fundamental perspective looks bearish. Easter holidays are...
Private placement of 1.736.346 shares at a price of 25.55€ made today to acquire "Résidence des Ardennes" (Attert, Belgium) makes the share price tumble more than 3.35% once trading is opened at 14:30h (closed since 9:00). Fibonacci retracement suggests buying at 24.80€. However, volatility in markets due to lockdowns may drag the price towards 18.80€ again but...
FUNDAMENTAL: The company improves EBITDA YoY +9.0% but misses Q4's by -31.3%. Net Sales (YoY) +2.6% but missed Q4 -7.0% Outlook for 2021: Net sales in 2021 slightly lower than in 2020. Operating profit estimated to be lower or clearly lower than in 2020. TECHNICAL: Fibonacci Retracement level suggests Orion's about to break 0.618 level downwards up until 29.60...
What should we do? Wait until it reaches 0.20? Or obey this harmonic pattern that may lead the way in the coming days? Maybe, in the psychological mindset of the investors that put money in this company there exists the thought of a +100% revaluation until January or February. Besides, the company has been recently included in the Ibex Small Cap index.
Looks like BBVA has hold still surpassing 4.37 resistance level this friday closing. In the short term, on February 12 we could see BBVA reach 5€ level and drop back down to 4.37€ again due to the bearish bat pattern that could have been shaped in the background. So long term technical perspective is bearish. However, keep in mind that BBVA plans to buyback 10% of...
If so, the stock could jump 4% tomorrow. It has been clearly oversold up until Fibonacci retracement level 0.5. Do not expect a trend change if tomorrow's results are better than expected.
With all vaccine turbulences (how many doses can each country get, bureaucracy and so on) and covid19 cases going up in Germany (lockdown already updated until January 31), could we expect the formation of a H&S pattern by the end of next week? Also, Deutsche Bank is insanely overvalued at 9.530€.
Long-term perspective is bullish. However, key support at 100 and 114. 18 February = limit date to buy.
Some regions of Spain have hardened anti-covid19 measures in order to stop (not even reduce) the contagion. For example, Catalonia's new measures are municipal confinement from the 7th to 17th January, with shopping malls and gyms closed. However, EURUSD getting higher might seduce investors to invest in Spain, a strongly punished market since March 2019. From a...
Even though the company has little debt and has performed quite good over its history, the threat of a worsening pandemic is dragging its price down. Will we see 10€ level once again?
We are always listening to "Sacyr wins this concession in Chile", "Sacyr wins this construction in ____", "Sacyr enters bid to build a hospital in Lisbon"... But what if there are overcosts or a new confinement? Nowadays, the company is unprofitable. In 2019, it lost €297 million and historically Sacyr has always been correlated with the price fluctuations of...
On July 10, after issuing a warning that the firm would expect higher than usual profits, BIOS jumped >20% that friday. Then, once its quarterly earnings were released, it was clear the company had not tricked us: + 25.8% REVENUES OF 14.3 MILLION IN THE FIRST SEMESTER, +44.2% to 5.5 million euros in Plant extracts business line, probiotics business registered a...
Low volume and triangle closing may initiate the start of a rebounce up to 4.50€ or a pullback until 3€ to rebounce from that level.
August 15: meeting with China. Will the trade war worsen? November 3: US elections. Before November 3, Trump expects to have the vaccine. What if the vaccine does not work? What if we are in a brand-new dotcom crisis? Investors will collect profits at 3390 from the S&P 500. It's the most safe movement they could do to mitigate their appetite of risk. So at 2930...
Biosearch is clearly improving its fundamental results but investors may not like that drop on EBITDA. That is why we could expect Biosearch go towards 0.50 Fib level at 0.876 and bounce back to 1.07 level, with the risk of losing 10% once the stock is bought at 0.876. So short the firm in the next 15 days, and long until you feel comfortable. It may also be a...
Over the past 5 years, August has been a bad month for the dollar except 2019, were DXY went up 2% in August. Long term bullish channel from April 2011 has seen DXY touch its lower bound this week and long-term bullish channel from Feb 2009 sees DXY approaching to its lower bound at 91, -3.15% from current level. Last week, DXY decreased 1.78% (biggest reduction...